Should you buy Bristol-Myers Squibb stock now?
Yes, the technical signal for Bristol-Myers Squibb is currently BUY. Bristol-Myers Squibb trades at $63.57 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 2.055 with rising momentum (signal: 1.818); RSI is at 60.2 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $66.21 points to 4.2% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Bristol-Myers Squibb stock?
The average analyst price target for Bristol-Myers Squibb is $66.21. The current price is $63.57, which gives an upside of 4.2%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $59.59 and $72.83.
Is Bristol-Myers Squibb a dividend stock?
Yes, Bristol-Myers Squibb is a dividend stock with a dividend yield of 3.81%. The latest dividend was $0.63 per share. The latest ex-dividend date (traded without the dividend) was 7/2/2026. The payout ratio is 38.6%, which is considered sustainable. The next dividend payment is scheduled for 8/3/2026.
When does Bristol-Myers Squibb pay a dividend in 2026?
Bristol-Myers Squibb pays its next dividend on 8/3/2026. The latest dividend was $0.63 per share with an ex-dividend date of 7/2/2026. The dividend yield is 3.81%. The payout ratio of 38.6% points to a sustainable dividend with room to grow.
What is the risk of Bristol-Myers Squibb stock?
Bristol-Myers Squibb is rated as a stock with moderately low risk. the annual standard deviation is 27.2%, which classifies the stock as moderately low risk.
Is Bristol-Myers Squibb overvalued?
Bristol-Myers Squibb is considered fairly valued – the price is close to the analyst price target. Bristol-Myers Squibb has the following valuation ratios: a P/E ratio of 14.0 (moderately valued), a P/S ratio of 2.6, a P/B ratio of 6.0. The stock trades close to the analyst price target and is considered fairly valued.
Is Bristol-Myers Squibb overbought?
No, Bristol-Myers Squibb is not overbought. RSI is at 60.2 (neutral zone). The technical indicators show: RSI is at 60.2 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 3.2% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Bristol-Myers Squibb earnings report?
The date of the next earnings report for Bristol-Myers Squibb has not been published yet. Check the company's investor calendar for updates.
Is Bristol-Myers Squibb shorted?
Yes, Bristol-Myers Squibb is shorted with 2.2% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Bristol-Myers Squibb stock?
No, insiders are not buying Bristol-Myers Squibb shares – they are net sellers. Over the last 3 months, insiders have made 1 purchases and 3 sales. On a net basis, 2,751,356 $ worth of shares were sold. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 8,267,681 $ sold. Active sellers include Massacesi Cristian, Gallman Cari, Short Bartie Wendy and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Bristol-Myers Squibb a good stock?
Based on our total score, Bristol-Myers Squibb is rated as a fantastic stock with a total score of 81 out of 100. The stock scores exceptionally high on value, quality and momentum – it is among the best 19% in our database. The score is made up of Value: 69/100, Quality: 90/100, Momentum: 83/100. In addition: a dividend of 3.81%; technical signal: Strong Buy. Whether Bristol-Myers Squibb is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Bristol-Myers Squibb stock?
The outlook for Bristol-Myers Squibb based on current data: the average analyst price target is $66.21 (+4.2%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 14.0 (low – a possible value stock). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Bristol-Myers Squibb stock rising?
Bristol-Myers Squibb is rising right now. The technical indicators show: the price is 3.2% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Bristol-Myers Squibb go?
The average analyst price target for Bristol-Myers Squibb is $66.21, which corresponds to a potential gain of 4.2% from the current price of $63.57. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Bristol-Myers Squibb fall?
We lack enough history to give a specific floor for Bristol-Myers Squibb. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Bristol-Myers Squibb do?
Bristol-Myers Squibb (bmy.us) driver en global forretning, hvor de opdager, udvikler og sælger biofarmaceutiske produkter. De tjener primært penge på lægemidler til behandling af alvorlige sygdomme inden for kræft, immunologi og hjerte-kar-området.
Blandt deres bedst kendte p... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Bristol-Myers Squibb as an investment.
Did Bristol-Myers Squibb raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Bristol-Myers Squibb. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Bristol-Myers Squibb making money or losing money?
Yes, Bristol-Myers Squibb is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 18.9% — which is solid. The operating margin (profit before interest and taxes) is 34.4%. At a P/E ratio of 14.0, you currently pay 14.0 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Bristol-Myers Squibb go bankrupt?
The bankruptcy risk of Bristol-Myers Squibb is rated as low. Altman Z2 (a model for assessing financial distress) is 2.90 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 467% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Bristol-Myers Squibb have a lot of debt?
Yes, Bristol-Myers Squibb has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 467%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Bristol-Myers Squibb service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 11.0x, and net debt equals 1.8 years of earnings (EBITDA).
